IPHA - innate-pharma.com Price to Earnings Adjusted for Growth Rate

The investment potential of Innate Pharma S.A. (IPHA) is based on strategic alliances with pharmaceutical giants to co-develop immunotherapies. A filter for undervalued "rockets" based on PEG was obtained from the GURU.Markets terminal, where 0.00 records the value of this parameter. The scaling model relies on receiving patent royalties, while absolute barriers to entry are ensured by the complexity of biosynthesis and strict FDA control.

The PEG ratio compares the earnings multiple to the growth rate, allowing for the determination of an asset's fair value relative to its expansion. By analyzing the adjusted P/E relative to growth rates, an investor identifies undervalued assets, which is critical for Innate Pharma S.A. (IPHA), whose capitalization depends on scalable royalties from the licensing of immunotherapeutic molecules without manufacturing costs.